Evidence map›Paper›PMID 36606689›Full record

ReviewPharmacotherapy2023

Precision fluid and vasoactive drug therapy for critically ill patients.

Seth R Bauer, Rochelle M Gellatly, Brian L Erstad

Open access · bronzeAbstract readReview
In one paragraph

Review in Pharmacotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Role of Tie-2 Axis in Sepsis: A Potential Therapeutic Target.Journal of cellular and molecular medicine · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Seth R BauerDepartment of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-0420-0320
Rochelle M GellatlyPharmacy Department, Surrey Memorial Hospital, Surrey, British Columbia, Canada.
Brian L ErstadDepartment of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona, USA.ORCID 0000-0001-8909-9921
Cleveland Clinic · USSurrey Memorial Hospital · CAUniversity of Arizona · US

Funding

Personalized vasopressor therapy in patients with septic shockK08GM147806 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI SETH BAUER · 2022 to 2026
$886k
NIGMS NIH HHS K08 GM147806NIGMS NIH HHS K08GM147806
6 · The paper itself

Abstract

There are several clinical practice guidelines concerning the use of fluid and vasoactive drug therapies in critically ill adult patients, but the recommendations in these guidelines are often based on low-quality evidence. Further, some were compiled prior to the publication of landmark clinical trials, particularly in the comparison of balanced crystalloid and normal saline. An important consideration in the treatment of critically ill patients is the application of precision medicine to provide the most effective care to groups of patients most likely to benefit from the therapy. Although not currently widely integrated into these practice guidelines, the utility of precision medicine in critical illness is a recognized research priority for fluid and vasoactive therapy management. The purpose of this narrative review was to illustrate the evaluation and challenges of providing precision fluid and vasoactive therapies to adult critically ill patients. The review includes a discussion of important investigations published after the release of currently available clinical practice guidelines to provide insight into how recommendations and research priorities may change future guidelines and bedside care for critically ill patients.

Indexed as

Critical IllnessFluid TherapyAdultCrystalloid SolutionsHumansCrystalloid Solutionsalbuminbalanced crystalloidsfluid therapynormal salineprecision medicinevasoactive drugs

Identifiers

PMID36606689
PMCPMC10323046
OpenAlexW4313649346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.